QuiaPEG

Newsroom

Se nyheter från:
Page:
123456789
Feb 01, 2019

QuiaPEG Pharmaceuticals Holding AB (publ), "QuiaPEG", today announces that the company has decided on a directed new issue of shares and warrants to three investors.

QuiaPEG Pharmaceuticals Holding AB ("the Company"), listed on Spotlight, today announces that the Company's Board of Directors made the decision on February 1, 2019, with the support of authorization from the Annual General Meeting on June 18, 2018, to carry out a directed new issue of 2,058,824 shares and 2,058,824 warrants.

Dec 18, 2018

QuiaPEG Pharmaceuticals Holding AB (publ) today announces that it has successfully registered the Uni-Qleaver® brand name in China.

Dec 11, 2018

QuiaPEG Pharmaceuticals Holding AB (publ) today announces that one of the five largest global pharmaceutical companies will place an initial order for activated PEGs (reagents) based on the Uni-Qleaver® platform.

Dec 10, 2018

QuiaPEG Pharmaceuticals Holding AB (publ) develops improved and patentable versions of clinically validated or approved drugs, so called biobetters. This is based on the company's proprietary patent-protected technology platform, Uni-Qleaver®, which allows a chosen release time for the drug through a controllable chemical coupling unit. After receiving positive pre- clinical trial results for QPG-1029, QuiaPEG today announces that it has signed a Material Transfer Agreement (MTA) with an Asian pharmaceutical company regarding the QPG-1029 drug project (peg-liraglutid), which has blockbuster1 potential in the indications diabetes and overweight.

Page:
123456789
Contact
QuiaPEG Pharmaceuticals Holding AB

Virdings Allé 32 B
754 50 Uppsala
Sweden
+46 (0) 70 693 12 53
info@quiapeg.com

User terms & privacy policy
Send a message